

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method for treating a ~~LFA-1 mediated disorder~~ **multiple sclerosis** in a mammal comprising administering to the mammal an initial dosing of a therapeutically effective amount of an ~~LFA-1 antagonist~~ **anti-CD11a antibody**, followed by a subsequent intermittent dosing of a therapeutically effective amount of ~~LFA-1 antagonist~~ **the antibody** that is less than 100%, calculated on a daily basis, of the initial dosing of the ~~antagonist antibody~~, **wherein the antibody is administered to the mammal not more than once per week during the subsequent intermittent dosing.**
2. (Currently Amended) The method of claim 1 wherein the subsequent dosing is less than about 50%, **calculated on a daily basis,** of the initial dosing of the ~~antagonist antibody~~. **antibody.**
3. (Currently Amended) The method of claim 1 wherein the subsequent dosing is less than about 25%, **calculated on a daily basis,** of the initial dosing of the ~~antagonist antibody~~. **antibody.**
4. (Currently Amended) The method of claim 1 wherein the subsequent dosing is less than about 10%, **calculated on a daily basis,** of the initial dosing of the ~~antagonist antibody~~. **antibody.**
5. (Currently Amended) The method of claim 1 wherein the subsequent dosing is less than about 2%, **calculated on a daily basis,** of the initial dosing of the ~~antagonist~~ **antibody.**
6. (Cancelled)
7. (Cancelled)
8. (Original) The method of claim 1 further comprising administering an effective amount of an immunosuppressive agent to the mammal.
9. (Cancelled)
10. (Original) The method of claim 1 wherein the mammal is a human.

11. (Cancelled)
12. (Original) The method of claim 1 wherein the subsequent dosing is carried out for a longer time than the initial dosing.
13. (Currently Amended) The method of ~~claim 6~~ **claim 1** wherein the initial dosing consists of daily administration ~~and the subsequent dosing is a dose administered no more than about once a week.~~
14. (Currently Amended) The method of ~~claim 13~~ **claim 1** wherein the ~~initial~~ **intermittent** dosing comprises daily administration of antagonist for at least one week after the ~~graft implant and the subsequent dosing comprises administration of agonist~~ **the antibody** no more than once biweekly for at least about 5 weeks after the end of the initial dosing.
15. (Cancelled)
16. (Currently Amended) The method of ~~claim 6~~ **claim 1** wherein the dosing is given by intravenous or subcutaneous injections.
- 17-20 (Cancelled)
21. (New) The method of claim 1 which does not deplete T-lymphocytes in the mammal.
22. (New) The method of claim 1, wherein the antibody is a chimeric antibody in which a CDR from one immunoglobulin class is substituted into another immunoglobulin class.
23. (New) The method of claim 1, wherein the intermittent dosing is administered to the mammal for at least about 5 weeks.
24. (New) The method of claim 1, wherein the intermittent dosing is administered to the mammal for at least about 10 weeks.